Evidence map›Paper›PMID 38402329›Full record

Trial reportScientific reports2024

Utilizing the sublingual form of squalene in COVID-19 patients: a randomized clinical trial.

Mahmoud Ebrahimi, Nafiseh Farhadian, Sara Saffar Soflaei, Alireza Amiri, Davoud Tanbakuchi, Rozita Khatamian Oskooee, Mohammad Karimi

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mahmoud EbrahimiCardiovascular Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Nafiseh FarhadianChemical Engineering Department, Faculty of Engineering, Ferdowsi University of Mashhad, Mashhad, Iran. n.farhadian@um.ac.ir.
Sara Saffar SoflaeiDepartment of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Alireza AmiriEmergency Medicine Department, Golestan University of Medical Sciences, Gorgan, Iran.
Davoud TanbakuchiDepartment of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
Rozita Khatamian OskooeeEmergency Medicine Department, Birjand University of Medical Sciences, Birjand, Iran.
Mohammad KarimiEmergency Medicine Department, Birjand University of Medical Sciences, Birjand, Iran.
Mashhad University of Medical Sciences · IRBirjand University of Medical Sciences · IRFerdowsi University of Mashhad · IRGolestan University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, the efficacy of sublingual squalene in decreasing the mortality rate among patients with COVID-19 was investigated. Squalene was extracted from pumpkin seed oil with a novel method. Then, the microemulsion form of squalene was prepared for sublingual usage. In the clinical study, among 850 admitted patients, 602 eligible COVID-19 patients were divided in two groups of control (N = 301) and cases (N = 301) between Nov 2021 and Jan 2022. Groups were statistically the same in terms of age, sex, BMI, lymphocyte count on 1

Indexed as

COVID-19HospitalizationHumansPatient DischargeSARS-CoV-2SqualeneTreatment OutcomeSqualeneCOVID-19Early treatmentMortality rateRe-hospitalizationSARS-COV-2Squalene

Identifiers

PMID38402329
PMCPMC10894301
OpenAlexW4392138268

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.